Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), a LAMA/ICS/LABA combination, significantly improves trough FEV1* in symptomatic patients with inadequately controlled asthma compared with FF/VI only, according to the CAPTAIN** study presented at AAAAI 2020.
Treatment with omalizumab, an anti-IgE monoclonal antibody, significantly improves outcomes in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), regardless of asthma status, based on a pooled analysis of the POLYP 1 and POLYP 2* studies presented at AAAAI 2020.
Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Adults who develop peanut allergy in adulthood are less likely to receive a physician diagnosis of their allergy or use epinephrine compared with those with childhood-onset peanut allergy, according to a study from the US.
Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.
Three studies initially scheduled for presentation at AAAAI 2020 demonstrated that epinephrine delivered intranasally was more rapidly absorbed and led to greater haemodynamic response compared with epinephrine delivered intramuscularly.
The investigational IGSC-C 20%* was noninferior and bioequivalent to, and had a similar safety profile with, IGIV-C 10%** for the treatment of primary humoural immunodeficiency (PI)***, highlighting the former’s potential as immunoglobulin (Ig)G replacement therapy for immune prophylaxis, according to phase III data presented at AAAAI 2020.